Press Releases BioInvent International AB

Equities

BINV

SE0015244520

Market Closed - Nasdaq Stockholm Other stock markets 11:29:52 2024-05-03 am EDT			5-day change	1st Jan Change
26.95 ^SEK	+2.28%		+7.16%	+42.14%

Apr. 30	BioInvent Announces Evaluating Attana Technology	CI
Apr. 24	BioInvent International AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioInvent International : Resolutions at BioInvent's Annual General Meeting 2024	May. 03	PU
Resolutions at BioInvent’s Annual General Meeting 2024	May. 03	AQ
BioInvent evaluating Attana Technology	Apr. 30	AQ
BioStock: BioInvent selected to present at ASCO in Chicago	Apr. 29	AQ
BioInvent International AB, Interim report January-March 2024	Apr. 25	AQ
BioInvent Q1 2024 - Approaching Catalysts	Apr. 25	AQ
BioInvent to Present Clinical Data from its two leading assets at ASCO 2024	Apr. 24	AQ
BioInvent International AB: Interim report January-March 2024	Apr. 24	AQ
BioInvent International AB publishes Annual Report 2023	Apr. 04	AQ
BioStock: BioInvent deepens collaboration with MSD	Apr. 04	AQ
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company s second anti-TNFR2 antibody in combination with KEYTRUDA	Apr. 03	AQ
BioInvent International : announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company's second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)	Apr. 02	PU
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company’s second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)	Apr. 02	AQ
Notice to Annual General Meeting in BioInvent International AB	Mar. 27	AQ
BioStock: BioInvent's CEO comments on the study success in China	Mar. 11	AQ
BioInvent International, CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed, Refractory Indolent Non-Hodgkin's Lymphoma In China	Mar. 06	AQ
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China	Mar. 05	PU
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma In China	Mar. 05	AQ
BioInvent International AB Year-end report January 1, December 31, 2023	Feb. 23	AQ
BioInvent Q4 2023 - Now a mid-stage clinical company	Feb. 23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BioInvent International AB

Equities

BINV

SE0015244520

Press Releases

Filters